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Abstract
Studies on activated cell-signaling pathways responsible for neoplastic transformation are
numerous in solid tumors and in adult leukemias. Despite of positive results in the evolution of
pediatric hematopoietic neoplasias, there are some high-risk subtypes at worse prognosis. The aim
of this study was to asses the expression and activation status of crucial proteins involved in cell-
signaling pathways in order to identify molecular alterations responsible for the proliferation and/
or escape from apoptosis of leukemic blasts. The quantitative and qualitative expression and
activation of Erk-1, c-Jun, Caspase8, and Gadd45a was analyzed, by immunocytochemical (ICC) and
western blotting methods, in bone marrow blasts of 72 patients affected by acute myeloid leukemia
(AML), T-cell acute lymphoblastic leukemia (ALL) and stage IV non-Hodgkin Lymphoma (NHL). We
found an upregulation of Erk-1, Caspase8, c-Jun, and Gadd45a proteins with a constitutive
activation in 95.8%, 91.7%, 86.2%, 83.4% of analyzed specimens, respectively. It is worth noting that
all AML patients showed an upregulation of all proteins studied and the high expression of
GADD45a was associated to the lowest DFS median (p = 0.04). On univariate analysis, only Erk-1
phosphorylation status was found to be correlated with a significantly shorter 5-years DFS in all
disease subgroups (p = 0.033) and the lowest DFS median in ALL/NHL subgroup (p = 0.04).
Moreover, the simultaneous activation of multiple kinases, as we found for c-Jun and Erk-1 (r =
0.26; p = 0.025), might synergistically enhance survival and proliferation potential of leukemic cells.
These results demonstrate an involvement of these proteins in survival of blast cells and,
consequently, on relapse percentages of the different subgroups of patients.
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Introduction
Aberrations in regulation of a restricted number of key
pathways that control cell proliferation and cell survival
are mandatory for tumour growth and progression.
Deregulated cell proliferation and suppressed apoptosis
are both essential for cell transformation and sustained
growth.
Hematological neoplasia are considered "special tumors"
for their high sensitivity to the occurrence of spontaneous
and pharmacological apoptosis. These cancers origin by
tissues that use apoptosis for the regulation of their phys-
iological mechanisms. These considerations explain the
high sensitivity of these diseases to chemotherapy. How-
ever, high risk haematologic disease subtypes, that display
a worse prognosis, also exist.
Acute lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), and non-Hodgkin Lymphoma (NHL)
are common cancer in children and teenagers [1]. Current
treatment approaches are tailored according to the clinical
characteristics of the host, genotype of the blasts, and
early response to therapy [2]. Although these approaches
have been successfully used in improving the outcome,
several children with high risk acute leukemia and stage IV
NHL still relapse. Cell drug resistance and cell-signaling
pathways could be involved as important determinants of
chemotherapy failure [3]. Programmed cell death, or
apoptosis, has emerged as a common mechanism by
which cells respond to cytotoxic drugs. However, the sig-
naling mechanisms that mediate drug-induced apoptosis
are still widely unknown.
Mitogen-activated protein kinase (MAPK) signaling cas-
cades trigger stimulus-specific responses in cells: in fact,
ERK is associated to proliferation and differentiation of
hematopoietic cells while C-Jun N-terminal kinases
(JNKs) are involved in stress-induced apoptosis and are
associated to T cell activation [4]. A recent study showed
that the JNK inhibition, in T-cell and Hepatocellular carci-
noma cell lines, induces anti-tumor activity by growth
arrest and CD95-mediated apoptosis through a transcrip-
tion-independent mechanism [5]. Upregulation of the
Ras/Raf/Mek/Erk pathways and phosphorylation of the
downstream target are frequently observed in adult ALL
and AML specimens and are associated to worse progno-
sis. In addition, it has been reported that Erk1 activation
may represent an independent prognostic factor for
achievement of complete remission in ALL and AML
patients [6,7].
Another crucial cell mechanism involved in leukemogen-
esis is an alterate DNA repair and cell cycle arrest. Gadd45
is one of several growth arrest, apoptosis and DNA-dam-
age-inducible genes. Interestingly, recent reports have sug-
gested that GADD45a and b proteins also function in
hematopoietic cell survival against genotoxic stress, in
apparent contradiction to the role that GADD45 proteins
family plays in apoptosis of epithelial and endothelial
cells [8]. These data indicated that, conversely to the pro-
apoptotic function of GADD45, in hematopoietic cells
both Gadd45a and Gadd45b genes play a survival role.
Induction of Gadd45 genes at the onset of myeloid differ-
entiation suggested that Gadd45a protein plays a role in
hematopoiesis [9].
Altered expression and activity of different components of
the apoptotic pathway, including receptors, ligands, adap-
tors, and caspases, can contribute to malfunction of the
apoptotic machinery and, ultimately, to a more malignant
phenotype. The ability of cytotoxic agents to trigger cas-
pase activation appears to be a crucial determinant of drug
response [10,11].
At our knowledge, the role of these molecular markers in
prognosis determination of malignant pediatric haemato-
logic neoplasms is still under-investigated. Moreover,
novel treatment modalities have been directed towards
inappropriately activated cell-signaling pathways that
may be responsible for the proliferation and/or escape
from apoptosis of leukemic blasts [12]. For this reason,
the aim of the present study was to evaluate the expression
and activity of cell-signaling-related proteins in blasts of
children and teenagers affected by high risk haematologic
neoplasms, such as AML, T cell ALL and stage IV NHL
characterized by bone marrow infiltration. These molecu-
lar features have been subsequently correlated to the clin-
ical outcome and to other biological prognostic factors.
Materials and methods
Patients
Seventy-two children with T cell ALL (18 samples), AML
(45 samples) and stage IV NHL (9 samples) diagnosed
and treated at the Oncology Pediatric Service of the Sec-
ond University of Naples were enrolled in this study. The
diagnosis was established by cytological examination of
bone marrow smears and cytochemical tests included the
staining for Periodic Acid Shiff (PAS), Myeloperoxidase
(MPO), Alpha-Naphthyl-Acetate Esterase (ANAE) and
Acidic Phosphatase (ACP). All samples presented a per-
centage of blast cells > 90%.
The patients with acute leukemias (AL) were sub-classified
as ALL or AML according to the French American British
(FAB) classification [[24], 25, 26] and NHL patients
according to the NCI classification according to "Working
Formulation". All NHL patients were stage IV for bone
marrow involvement. The AML patients were treated
according to AIEOP-AML protocols ('87, '92, '01–'02),
ALL and NHL patients according to AIEOP-ALL protocols
('95, '00) [13].Journal of Experimental & Clinical Cancer Research 2009, 28:39 http://www.jeccr.com/content/28/1/39
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Immunocytochemistry
The bone marrow slides, collected at diagnosis, were fixed
in acetone-methanol solution (1:1 dilution) for 30 sec-
onds at 4°C. Mouse anti-human monoclonal antibodies
raised against JNK phosphorylated on Serine-63, anti-
Caspase8 p20 for p-20 subunit, anti-human Gadd45a
(amino acids 1–165) and anti-pErk-1 phosphorylated on
Tyrosine-204 were purchased from Santa Cruz Biotecnol-
ogy (Santa Cruz, CA). All the primary antibodies were
used at 1:100 dilution and added to the slides for 30 min-
utes at 37°C.
After three washes in Tris buffer, the Alkaline Phos-
phatase-conjugated Envision System DAKO was used to
visualize the sites of localization of the different proteins
expressed in bone marrow cells. This kit is unaffected by
endogenous Alkaline Phosphatase activity because
includes as blocking reagent levamisole and shows high
sensitivity. Fast Red was used as the final chromogen.
Cells were counterstained with Mayer's hematoxylin solu-
tion. HL60 cell-line cytocentrifuged slides were used as
positive controls. Negative controls for each reaction were
performed leaving out the primary antibody. Stained
slides were analyzed for percentage of positive cells by two
independent investigators. All samples were processed
under the same conditions. The specificity of staining was
also confirmed by competition of the primary antibodies
with the respective peptide against which they were gener-
ated (data not shown).
The staining pattern of the four proteins was evaluated
separately and the protein expression was scored in each
specimen for the percentage of positive neoplastic cells:
score 0 = undetectable staining; score 1 = from 1 to 30%
of positive cells; score 2 = more than 30% of positive cells.
Written informed consent was obtained from the parents.
Analysis of the data using such arbitrary cut-offs was sta-
tistically significant and, therefore, functionally operative.
The intensity of the staining was also evaluated for all pro-
teins and scored in low and intermediate/high intensity
compared with the 3+ Bcl-2 intensity of staining of the
background lymphocytes to produce a semiquantitative
evaluation of the immunostaining as previously described
(Wang Y, Kristensen GB, Helland A, Nesland JM, Borre-
sen-Dale AL, Holm R. 2005. Protein expression and prog-
nostic value of genes in the erb-b signaling pathway in
advanced ovarian carcinomas. Am J Clin Pathol 124:392–
401.).
Western blot analysis
For cell extract preparation, the blasts were washed twice
with ice-cold PBS/BSA, scraped, and centrifuged for 30
min at 4°C in 1 ml of lysis buffer (1% Triton, 0.5%
sodium deoxycholate, 0.1 NaCl, 1 mM EDTA, pH 7.5, 10
mM Na2HPO4, pH 7.4, 10 mM PMSF, 25 mM benzami-
din, 1 mM leupeptin, 0.025 units/ml aprotinin). Equal
amounts of cell proteins were separated by SDS-PAGE.
The proteins on the gels were electro-transferred to nitro-
cellulose and reacted with Rabbit antisera raised against
α-tubulin, pErk-1/2 K-23, and Erk C-14 purchased from
Santa Cruz Biotechnology (Santa Cruz, CA).
Statistical analysis
Standard statistical description of parameters were used to
characterize the data (mean, median and range). Spear-
man correlation test or chi-square test was used to assess
the relationship between clinical parameters and immu-
nocytochemical data. All p values are two-sided and val-
ues less than 0.05 were considered statistically significant.
Disease free survival (DSF) probability was calculated by
Kaplan Meier method; comparison between probabilities
in different groups was performed using the log-rank test.
In DFS analysis, relapse and death due to any cause were
considered treatment failures. DFS was calculated for all
patients that obtained complete remission from the date
of remission to relapse, death or date of last follow-up.
The remission status of the patients was determined on
morphologic bases and complete remission was defined
as less than 5% blasts in a normocellular bone marrow.
Complete disappearance of all visible disease was
required for NHL patients. If complete remission was not
achieved (resistant patients) DFS was recorded as 0.
In the univariate analysis of DFS, the following variables
were evaluated: gender, age, white blood cells at diagnosis
and type of hematological neoplasia.
Results
Patient characteristics
Seventy-two patients (24 females and 48 males) were
included in this study. The age of patients ranged from 0.5
to 13.7 years (median, 6.2 years). Clinical and pathologi-
cal data of the 72 patients are listed in table 1. Eighteen
patients (25%) had T cell ALL, forty-five (62.5%) had
AML (no M3 subtype) and nine (12.5%) had stage IV
NHL disease. At presentation, forty-one patients (57%)
had white blood cells (WBC) higher than 20,000/mmc
and thirty-one (43%) a lower count. Morphologically, the
AML patients were classified as M0 (1 case), M1 (5 cases),
M2 (18 cases), M4 (10 cases) (two of which were second-
ary leukemia), M5 (8 cases), M6 (1 case), M7 (2 cases); T-
cell ALL cases as L1 (1 case) and L2 (17 cases). The NHL
patients were classified as Burkitt-like (1 case), T-cells (3
cases) and B-cells (5 cases) (14) (tab. 1).Journal of Experimental & Clinical Cancer Research 2009, 28:39 http://www.jeccr.com/content/28/1/39
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Qualitative and quantitative analysis of Gadd45a, pErk-1, 
pJNK and Caspase 8
Table 2 summarizes the results of the immunocytochem-
ical analysis related to % of blasts with protein activation
and intensity of the staining.
In details, 30 specimens showed low and 30 high
Gadd45a expression levels (83.4%), while in 12 samples
(16.6%) the protein was absent. Immune-reactivity,
detected in the nuclei and cytoplasms of blasts, showed
high or low staining intensity in 40/60 samples (66.7%)
and 20/60 samples (33.3%), respectively (Figure 1A).
Erk-1 activation, was detected in 69 of 72 evaluated spec-
imens (95.8%): score 1 and 2 in 30.5% and 65.3%,
respectively. The intensity of nuclear staining showed low
or intermedie/high staining in 18.8% and 81.2% samples,
respectively (Fig. 1B). JNK activation showed score 1 or
score 2 in 50% (36/72) and 36.2% (26/72) samples,
respectively. The p-JNK nuclear and cytoplasmic staining
intensity was low or intermediate/high in 25.8% (16/62)
and 74.2% (46/62) samples, respectively (Fig. 1C).
Caspase8 was undetectable in 8.3% (6/72) and detected
in 91.7% (66/72) samples, respectively. In details, score 1
or score 2 was detected in 44.4% (32 samples) and 47.3%
(34 samples), respectively. Intermediate/high or low
intensity cytoplasmatic staining of Caspase8 was detected
in 68.2% (45/66) and 31.8% (21/66) samples, respec-
tively (Fig. 1D and Table 2).
The statistical analysis of these data showed that the stain-
ing intensity of the four analyzed proteins directly corre-
lated with the number of positive cells (p < 0.05).
Moreover, we found a simultaneous activation of pJNK
and Erk-1 in the evaluated blasts (r = 0.26; p = 0.025). In
order to validate the results obtained in ICC, we have eval-
uated the expression of p-Erk-1 with western blotting with
conventional antibodies used for the determination of p-
Erk-1 and 2 and total Erk-1/2. The lower band shown in
the gel, corresponding to a M.W. of 44 KDa, is clearly
assessable in all the samples. The activity of the enzyme in
the different evaluable patients strongly correlated to that
one derived from experiments performed on blasts with
ICC. An example of Erk-1 expression and activity on 10
different samples is now shown in Figure 2. Similar results
were also obtained on all the other samples (data not
shown).
Protein activation levels in different groups subdivided for 
type of disease
When patients where subdivided into two different
groups according to the diagnosis of neoplastic disease
(ALL/NHL vs AML) we found a statistically significant dif-
ference of Gadd45a (p < 0.0001), pJNK (p = 0.0001), and
Caspase8 (p = 0.004) between AML and ALL/NHL
patients. Conversely, no difference in the phosphoryla-
tion of Erk-1 was detectable (p = 0.09). Interestingly, all
Table 1: Clinical characteristics of patient enrolled in the study
Variable No. of samples %
AGE
≤ 24 months 10 13.9
> 24 months 62 86.1
SEX
MALES 48 65.3
FEMALES 24 34.7
WBC
< 20000/mmc 31 43
≥ 20000/mmc 41 57
Tumour type
AML 45
M0 1 1.4
M1 5 7
M2 18 25
M4 10 13.8
M5 8 11
M6 1 1.4
M7 2 2.8
ALL-Tcells 18
L1 1 1.4
L2 17 23.6
NHL 9
T cells 3 4.2
B cells 5 7
Burkitt 1 1.4
Table 2: Distribution of protein activation or expression and staining intensity in blasts derived from haematological neoplasms
Marker Activated status
Number of patients (%)
Staining Intensity
Number of patients (%)
negative 1–30% >30% Low Intermediate/high
Gadd45a 12 (16.6%) 30 (41.7%) 30 (41.7%) 20 (33.3%) 40 (66.7%)
pErk-1 3 (4.2%) 22 (30.5%) 47 (65.3%) 13 (18.8%) 56 (81.2%)
JNK 10 (13.8%) 36 (50%) 26 (36.2%) 16 (25.8%) 46 (74.2%)
Caspase8 6 (8.3%) 32 (44.4%) 34 (47.3%) 21 (31.8%) 45 (68.2%)Journal of Experimental & Clinical Cancer Research 2009, 28:39 http://www.jeccr.com/content/28/1/39
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AML patients showed an upregulation of the four studied
proteins (Table 3).
Correlation between constitutive proteins activation and 
outcome
At the time of this analysis 23 patients (31.9%) were alive
in continuous complete remission, three patients (5.5%)
alive in second complete remission, and 46 patients
(63.8%) died from their disease.
Estimated 5-year DFS and OS rates for all patients were
31.9% and 36.1%, respectively.
By univariate analysis (log rank test) gender, age at diag-
nosis, WBC count and neoplasm type did not significantly
influence the overall survival. The Kaplan-Meier method
was used to assess any relationship between the studied
molecular markers and patient survival time (Table 4).
Erk-1 activation was confirmed to be an important prog-
nostic factor (p = 0.033). However, the other molecular
markers did not show any statistically significant correla-
tion with overall survival.
The analysis of DFS and of percentage of relapses in AML
+ NHL patients showed a statistically significant correla-
tion with Gadd45a expression. In fact, patients with lower
Gadd45a expression score had a better survival (p =
0.042) with a median DFS of 172 vs 11,5 months for score
1 and 2, respectively (Fig. 3A). Similarly, the analysis of
pERK1 score in the same group of patients revealed an
inverse correlation between pErk-1 scores and DFS (p =
0.04). In fact, median DFS was of 5, 16 and 21 months in
scores 3, 2 and 1, respectively (Fig. 3B).
Discussion
The understanding of signals and pathways that regulate
cell proliferation and apoptosis is crucial in searching for
devices capable to treat cancer.
The knowledge of molecular bases of cancer has undoubt-
edly demonstrated that the inappropriate expression and
activity of particular proteins involved in inter- and intra-
cellular signaling networks causes radical changes in cell
Table 3: Proteins status in neoplasia subgroups
GADD45a pERK-1 c-JUN CASP ASE8
Score 012 p 0 12 p 012 p 0 1 2 p
ALL/NHL 12 12 3 < 0.001 31 01 4 0 . 0 9 1 01 0 7 0.0001 61 01 10.004
AML 0 18 27 0 12 33 0 26 19 0 22 23
p values in bold are statistically significant.
Representative ICC for JNK (A), pErk-1 (B), Gadd45a (C)  and Caspase8 (D) Figure 1
Representative ICC for JNK (A), pErk-1 (B), Gadd45a 
(C) and Caspase8 (D). (A) JNK nuclear immune-reactivity 
in positive bone marrow blasts. (B, C) pErk-1 and Gadd45a 
nuclear and cytoplasmic staining in blasts. (D) Caspase8 cyto-
plasmic immune-staining in bone marrow blasts. Arrows 
show positive red stained cells.
Western blot assay for the expression of pErk 1 and 2 and  total Erk 1 and 2 Figure 2
Western blot assay for the expression of pErk 1 and 2 
and total Erk 1 and 2. The cells were processed for the 
determination of the phosphorylation and expression of Erk-
1 and 2 evaluated after blotting with a specific anti-pMAPK 
and an anti-MAPK Mab, respectively, as described in "Materi-
als and Methods". Expression of the house-keeping protein 
α-tubulin was used as loading control. In the same figure, the 
scores of the staining intensities of pErk-1 obtained at ICC in 
the same samples are also shown. The experiments were 
performed at least three different times and the results were 
always similar.Journal of Experimental & Clinical Cancer Research 2009, 28:39 http://www.jeccr.com/content/28/1/39
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behaviour, enabling prolonged cell survival and unlim-
ited proliferative capacity. [15,16] In this study we
focused on the role of signal transduction pathways that
control genomic stability and apoptosis in the prediction
of clinical outcome of haematological malignancies. In
details, the in vivo constitutive activation of Erk-1, JNK,
Gadd45a and Caspase8 was evaluated in high-risk hae-
mathological neoplasms. The immunocytochemical
method was used for the investigation in order to avoid
the contamination of the data by normal cells and allow
the observation of protein status in single leukemic cells.
It was found a constitutive activation of all the studied
proteins especially in AML. Moreover, high Gadd45a
expression (as both score and intensity) was associated
with low DFS median. Our results suggest an alteration of
the pathway that contributes to the maintenance of
genomic stability by upregulation of Gadd45a [16]. To
date, the involvement of Gadd45a in ALL has been
observed only in vitro in leukemic cell lines [18]. In a pre-
vious study we observed that alteration of anti-apoptotic
proteins such as Bcl-xl has been associated to increased
tumour cell survival [23]. The present report shows, for
the first time, that constitutive in vivo upregulation of
Gadd45a in leukemic blasts promotes neoplastic hemat-
opoietic cell survival that, based on our previous observa-
tions, probably occurs via p38 kinase and Bcl-xl. Another
Kaplan Meier DFS percentage plots in AML patients and ALL/NHL patients according to Gadd45a expression (A) and Erk1  activation level (B) Figure 3
Kaplan Meier DFS percentage plots in AML patients and ALL/NHL patients according to Gadd45a expression 
(A) and Erk1 activation level (B). Gadd45a 1: score 1; Gadd45a 2: score 2. Erk-1 0: score 0; Erk-1 1: score 1; Erk-1 2: 
score 2.
Table 4: Outcome of patients studied and proteins status
GADD45a pERK1 c-JUN CASPASE 8
Score 0 1 2 p 01 2 p 012p 01 2p
ALL/NHL 12 12 3 0.004 3 10 14 0.8 10 10 7 0.9 6 10 11 0.8
Resistant/Relapse 12 0 0 3 6 9 10 8 7 6 7 9
AML 0 1 82 7 0 . 9 01 23 30 . 5 0 2 61 9 0 2 2 2 3
Resistant/Relapse 0 15 20 0 5 24 0 10 12 0.4 0 11 14 0.8
Score 0 = negative; 1 = 1–30% of positive cells; 2: > 30% of positive cells; p values in bold are statistically significant.Journal of Experimental & Clinical Cancer Research 2009, 28:39 http://www.jeccr.com/content/28/1/39
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survival pathway over-activated in cancer cells is the Erk-
1/2-mediated pathways and it was previously reported
that Erk-1 activation may represent an independent prog-
nostic factor for achievement of complete remission in
ALL and AML patients [6,7]. We have indeed found that
higher activation of this protein is a predictive marker of
decreased overall survival in all diseases examined in the
study and of reduced DFS in ALL/NHL subgroup. Interest-
ingly, the staining intensity was correlated to the number
of positive cells. This correlation clearly showed that an
increase in the percentage of positive tumour cells corre-
lates with a quantitative increase in protein phosphoryla-
tion in the leukemic elements. Activation of Erk-1 results
in phosphorylation of many targets that have growth-pro-
moting and pro-survival effects and it is not surprising
that its activation correlates with a bad prognosis [19].
Moreover, in our series we observed an increased activa-
tion of JNK in 86% of patients (62/72) and the latter is
involved in the stress-activated signaling cascades suggest-
ing higher susceptibility of blasts to damage. Our results
indicate that the activation of the signal transduction
pathways components such as Erk-1 and JNK is very fre-
quent in these poor prognosis subgroup disease. The
simultaneous activation of multiple signaling pathways,
might synergistically enhance survival and proliferation
potential of leukemic cells protecting them from natural
or pharmacologically-induced stress. In fact, the disrup-
tion of these signaling, is demonstrated to contribute to
leukemogenesis by perturbing the rates of proliferation,
differentiation and apoptosis [22-24]. In conclusion, this
study confirms the relevant role of the MAPK pathway
and/or other potentially involved signaling pathways in
the pathogenesis and prognosis of high risk hematologi-
cal diseases. Nevertheless, additional studies are required
to define better the prognostic impact of these proteins.
Moreover, small inhibitors targeting the MAPK pathway
and/or other potentially involved signaling pathways,
must be evaluated to establish whether this targeted ther-
apeutic modality may add benefit (antiproliferative and/
or pro-apoptotic) to current treatments of childhood
leukemias and NHL, especially for high risk patients.
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